ERBB2 and breast cancer: The BEVERLY-2 study [38] is a relevant clinical trial focusing on the non-metastatic HER2-positive invasive BC, which encompassed CTC detection and pCR and provided validating evidence of their combined prognostic impact on DFS assessment.